Founded by Advent Life Sciences, Amphista is a spin-out of TPD expert Professor Alessio Ciulli’s laboratories at the University of Dundee. The Company has raised over $60M to date and is funded by leading life science investors including Forbion, Gilde Healthcare, Novartis Venture Fund, Advent Life Sciences, Eli Lilly & Company and The Dementia Discovery Fund. Amphista is a leader in next generation targeted protein degradation (TPD) approaches and is currently applying its proprietary degrader platform to advance new approaches in TPD. The Company aims to address the challenges faced by earlier stage TPD research and transform the lives of patients with severe diseases including cancer and central nervous system diseases.
When seeking to reinforce the company’s senior scientific leadership capability, Amphista entrusted Sally Hope and Tom Bradley to undertake the search mandate for a Senior Vice President of Chemistry for the organisation. As a result of an extensive search, Dr. Giles Brown was appointed to work with the leadership team and scientists to advance the Company’s drug discovery pipeline and deliver therapeutic candidates.
Giles Brown, Senior Vice President of Chemistry of Amphista Therapeutics, stated: “PIR International were fantastic during the process of recruiting me for the position of SVP Chemistry at Amphista. Sally Hope was extremely helpful with ensuring I had a good understanding of the role and what the organisation were looking for. She made me feel valued and kept me constantly updated on the process. Communication was flawless and any queries I had were swiftly answered. I’d like to thank both PIR International and Sally Hope there help and expertise during the process. I am excited to be joining a team of innovators to advance Amphista’s chemistry-led strategy and progress the pipeline to deliver potential medicines for many hard-to-treat diseases.”
Louise Modis, Chief Scientific Officer of Amphista Therapeutics added: “We are grateful to Sally and Tom for their thoughtful and professional approach during the recruitment process. Their expansive network and experience of the industry gave us access to a broad pool of high-quality candidates. We are absolutely delighted that we were able to bring Giles into the Amphista team. He is an exceptional chemist and leader with an outstanding track record of drug discovery. We look forward to opportunities to work with PIR in the future.”
Louise Modis, Chief Scientific Officer, Amphista Therapeutics